Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 8

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 8
---
. The forward-looking statements in this prospectus are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to several known and unknown risks, uncertainties, and assumptions. Although we believe the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. These forward-looking statements present our estimates and assumptions only as of the date of this prospectus. Accordingly, you are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those summarized below:

| ● | our ability to execute on our business strategy, including our plans to develop and commercialize a proprietary Rx-to-OTC switch technology; |

| ● | market acceptance of, any of our products or product candidates, including our proprietary Rx-to-OTC switch technology; |

| ● | our ability to use cash on hand to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures; |

| ● | if we are unable to effectively implement or manage our growth strategy, our operating results and financial condition could be materially and adversely affected; |

| ● | our ability to secure licensing agreements with potential customers; |

| ● | our ability to comply with data privacy laws, such as HIPPA; |

| ● | our ability to generate sustainable revenue from licensing arrangements; |

| ● | our ability to comply with obligations as a public reporting company; |

| ● | our ability to maintain compliance with The Nasdaq Capital Market’s listing standards; |

| ● | our ability to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; |

| ● | the potential impact of changes in the legal and regulatory landscape, both within and outside of the U.S.; |

1

| ● | our